EyePoint Pharmaceuticals (EYPT) AI Stock Analysis

• Market Cap: $761.06M
• Dividend Yield: N/A
• Average Volume (3M): 845.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.26
• Revenue Growth: 12.04%
• EPS Growth: -31.81%
• Country: US
• Employees: 165
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 68,811,740
• 10 Day Avg. Volume: 808,841
• 30 Day Avg. Volume: 845,946
• PEG Ratio: -0.02
• Price to Book (P/B): 1.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.94
• Enterprise Value/Market Cap: 0.10
• Enterprise Value/Revenue: 0.41
• Enterprise Value/Gross Profit: 1.53
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $23.81
• Price Target Upside: 115.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 59 Neutral
• Price Target: $11.50 ▲(3.98%Upside)

EyePoint Pharmaceuticals' overall stock score is driven by strong technical indicators and positive corporate events. However, significant challenges in financial performance and valuation weigh heavily on the score. The company's strategic focus on DURAVYU provides growth potential but must be balanced against current profitability issues.

Positive Factors

Clinical Trials

The rapid pace of enrollment in the LUGANO trial indicates enthusiasm among the wet AMD community for a treatment option with 6-month redosing.

Financial Stability

The company has a cash runway into 2027, which supports its financial stability.

Product Potential

Duravyu is seen as a potential best-in-class product that may reduce the treatment burden in retinal diseases, addressing a significant unmet medical need in wet AMD.

Negative Factors

Clinical Trial Risks

Risks include potential failure of DURAVYU in clinical trials, failure to obtain regulatory approval, and failure to achieve commercial success.

Financial Performance

Net loss was $45.2M, moderately higher than the estimated loss of $42.9M.

Market Competition

Despite the market entry of Eylea biosimilar, Pabvlu (AMGN, Not rated), management expects minimal impact on Duravyu due to its different MOA and durability, which will favor payor negotiations.

EyePoint Pharmaceuticals Business Overview & Revenue Model

Company Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

EyePoint Pharmaceuticals generates revenue primarily through the sale of its ophthalmic products, which are developed to address unmet medical needs in eye care. The company's revenue streams include product sales, royalties, and licensing fees from partnerships with other pharmaceutical companies. EyePoint collaborates with strategic partners to enhance the distribution and commercialization of its products, thereby expanding its market reach. Additionally, the company may receive milestone payments and research funding from its collaborations, which contribute to its overall earnings.

EyePoint Pharmaceuticals Financial Statement Overview

Summary

EyePoint Pharmaceuticals shows a positive revenue growth trajectory of 29.5% but faces significant challenges with negative net profit margins and cash flow issues. The balance sheet is strong with low leverage, yet profitability and cash flow management need improvement for sustainable growth.

Income Statement

EyePoint Pharmaceuticals shows a mixed performance. Revenue grew from 2024 to TTM (Trailing-Twelve-Months) by 29.5%, indicating a positive growth trajectory. However, profitability remains a concern with significant negative net profit margins of -261.8% in TTM, alongside negative EBIT and EBITDA margins. This suggests challenges in controlling costs and generating profits despite increasing revenues.

Balance Sheet

The company maintains a strong equity position, with a debt-to-equity ratio of only 0.08 in the TTM (Trailing-Twelve-Months). The equity ratio stands at 82.3%, indicating a solid balance sheet with low leverage. However, the return on equity is negative, reflecting ongoing profitability challenges that may affect future financial stability.

Cash Flow

EyePoint Pharmaceuticals faces significant cash flow issues. The free cash flow is negative, and the operating cash flow to net income ratio is unfavorable, indicating that the company is using more cash in operations than it generates. The free cash flow to net income ratio is also negative, highlighting a need for improved cash management and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.04M	43.27M	46.02M	41.40M	36.94M	34.44M
Gross Profit	52.28M	39.56M	41.39M	33.08M	28.76M	28.61M
EBITDA	-152.38M	-129.23M	-69.00M	-96.62M	-50.15M	-35.49M
Net Income	-146.78M	-130.87M	-70.80M	-124.51M	-63.91M	-52.65M
Balance Sheet
Total Assets	362.56M	418.46M	355.18M	180.36M	263.37M	91.72M
Cash, Cash Equivalents and Short-Term Investments	318.19M	370.91M	331.05M	144.56M	211.56M	44.91M
Total Debt	24.08M	21.86M	4.91M	45.77M	38.42M	40.31M
Total Liabilities	64.17M	81.96M	88.86M	83.99M	78.99M	73.18M
Stockholders Equity	298.40M	336.50M	266.32M	96.37M	184.38M	18.54M
Cash Flow
Free Cash Flow	-151.31M	-130.28M	-1.61M	-67.16M	-50.25M	-14.80M
Operating Cash Flow	-148.18M	-126.23M	1.88M	-65.00M	-50.10M	-14.44M
Investing Cash Flow	-200.64M	-219.35M	-3.31M	-17.27M	-33.12M	-362.00K
Financing Cash Flow	162.96M	164.02M	187.07M	-690.00K	216.90M	37.49M

EyePoint Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Positive. The current price of 11.06 is above the 20-day moving average (MA) of 9.56, above the 50-day MA of 7.95, and above the 200-day MA of 7.87, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 61.62 is Neutral, neither overbought nor oversold. The STOCH value of 67.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EYPT.

EyePoint Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TBRG	62 Neutral	$344.94M	―	-10.98%	―	3.15%	61.71%
RGNX	61 Neutral	$462.06M	―	-47.44%	―	80.70%	46.66%
EYPT	59 Neutral	$761.06M	―	-53.54%	―	12.04%	-31.81%
ZVRA	59 Neutral	$632.10M	―	-204.78%	―	44.92%	-40.06%
TSHA	50 Neutral	$664.29M	―	-159.34%	―	-48.97%	69.32%
Sector *	46 Neutral	C$203.97M	-3.15	-23.14%	2.72%	21.17%	-0.61%
ALDX	37 Underperform	$287.50M	―	-65.19%	―	―	-47.28%

EyePoint Pharmaceuticals Corporate Events

EyePoint Pharmaceuticals Approves Share Increase at Annual Meeting

On June 18, 2025, EyePoint Pharmaceuticals held its Annual Meeting of Stockholders via webcast, where stockholders approved an amendment to increase the number of shares in the 2023 Long-Term Incentive Plan by 2,900,000 shares. Additionally, the meeting included the election of directors, approval of executive compensation, and ratification of Deloitte & Touche LLP as the independent auditor, reflecting strong shareholder engagement and strategic alignment with the company’s growth objectives.

The most recent analyst rating on (EYPT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

EyePoint Completes Enrollment for DURAVYU Phase 3 Trial

On May 27, 2025, EyePoint Pharmaceuticals announced the completion of patient enrollment in the Phase 3 LUGANO clinical trial for DURAVYU, a treatment for wet age-related macular degeneration (wet AMD). This milestone was achieved with over 400 patients enrolled in seven months, marking one of the fastest enrollments for a Phase 3 trial in wet AMD. The trial’s rapid progress reflects strong interest from both patients and physicians, highlighting the commercial potential of DURAVYU. The LUGANO trial, along with the ongoing LUCIA trial, aims to assess the efficacy and safety of DURAVYU, with topline data expected in mid-2026. The trials are designed to evaluate the potential of DURAVYU to transform treatment paradigms for wet AMD, offering a sustained-release option that could reduce treatment burdens and improve patient compliance.

The most recent analyst rating on (EYPT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

EyePoint Pharmaceuticals Reports Q1 2025 Financial Results

On May 7, 2025, EyePoint Pharmaceuticals announced its first quarter 2025 financial results and recent corporate developments. The company reported significant progress in its Phase 3 trials for DURAVYU in wet AMD, with enrollment exceeding expectations, positioning DURAVYU for a potential first-to-market advantage. Additionally, EyePoint highlighted compelling data from the Phase 2 VERONA trial in DME, reinforcing DURAVYU’s potential as a paradigm-shifting treatment. Financially, EyePoint reported increased net revenue primarily due to deferred revenue recognition from a previous out-license agreement, despite a net loss for the quarter. The company maintains a strong cash position, expected to fund operations into 2027.